Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00002621 · ClinicalTrials.gov registry record · Phase 2

Interferon Alfa in Treating Children With HIV-Related Cancer

A Phase 2 study of Lymphoma and Leukemia, sponsored by Children's Oncology Group.

Completed
Registry status
Phase 2
Development phase
8
Enrollment target
10
Study locations

NCT00002621: Completed Phase 2 study of Lymphoma and Leukemia, sponsored by Children's Oncology Group.

NCT00002621 is a Phase 2 study of Lymphoma and Leukemia that has completed, run by Children's Oncology Group. The registered enrollment target is 8 participants, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (98% lower). The trial reports 10 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00002621, a Phase 2 study of Lymphoma and Leukemia, has completed, sponsored by Children's Oncology Group.

COMPLETED
Registry status
Phase 2
Development phase
8 participants
Enrollment target
10
Study locations

Study Summary

RATIONALE: Interferon alfa may interfere with the growth of cancer cells. PURPOSE: Phase II trial to study the effectiveness of interferon alfa in treating children with an HIV-related cancer including leukemia, non-Hodgkin's lymphoma, CNS lymphoma, or other solid tumors.

Conditions Studied

Lymphoma Leukemia Unspecified Childhood Solid Tumor, Protocol Specific

Interventions

  • BIOLOGICAL recombinant interferon alfa

Study Locations (10)

Texas

  • Medical City Dallas Hospital - Dallas
  • San Antonio Military Pediatric Cancer and Blood Disorders Center - Lackland Air Force Base
  • University of Texas Health Science Center at San Antonio - San Antonio

Other

  • University of Puerto Rico School of Medicine Medical Sciences Campus - San Juan
  • Clinique de Pediatrie - Geneva

Kansas

  • Via Christi Regional Medical Center - Wichita

Louisiana

  • MBCCOP - LSU Health Sciences Center - New Orleans

New Jersey

  • Tomorrows Children's Institute - Hackensack

North Carolina

  • Mission Saint Joseph's Health System - Asheville

Quebec

  • McGill University Health Center - Montreal Children's Hospital - Montreal

Trial Details

FieldValue
Enrollment Target 8 participants
Start Date 1994-12
Est. Completion 2005-09
Phase Phase 2
Children's Oncology Group

342 total trials

What the finished NCT00002621 record still lists

NCT00002621 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (98% lower).

The record links to 3 conditions, with Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which recombinant interferon alfa is the first listed.

NCT00002621 lists 10 locations in 7 states (Texas, Other, Kansas).

Frequently Asked Questions

What is clinical trial NCT00002621 about?

NCT00002621 is a clinical study titled "Interferon Alfa in Treating Children With HIV-Related Cancer". RATIONALE: Interferon alfa may interfere with the growth of cancer cells. PURPOSE: Phase II trial to study the effectiveness of interferon alfa in treating children with an HIV-related cancer including leukemia, non-Hodgkin's lymphoma, CNS lymphoma, or other solid tumors.

What is the current status of trial NCT00002621?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 1994-12. Estimated completion is 2005-09.

What conditions does trial NCT00002621 study?

This clinical trial studies the following conditions: Lymphoma, Leukemia, Unspecified Childhood Solid Tumor, Protocol Specific.

What interventions are being tested in trial NCT00002621?

The interventions under investigation include: recombinant interferon alfa (BIOLOGICAL).

Who is sponsoring clinical trial NCT00002621?

This trial is sponsored by Children's Oncology Group, which has 342 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00002621 being conducted?

This trial has 10 study locations across Kansas, Louisiana, New Jersey, North Carolina, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Lymphoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00002621's enrollment target sits among peer trials

8 283rd of 299 higher than 15 of 299 other Lymphoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00002621, the US trial registry maintained by the National Library of Medicine. NCT00002621 (small enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.